HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration

Two similarly designed phase 3 trials (HAWK and HARRIER) compared brolucizumab, a single-chain antibody fragment that inhibits vascular endothelial growth factor-A, with aflibercept to treat neovascular age-related macular degeneration (nAMD). Double-masked, multicenter, active-controlled, randomize...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Ophthalmology (Rochester, Minn.) Jg. 127; H. 1; S. 72
Hauptverfasser:	Dugel, Pravin U, Koh, Adrian, Ogura, Yuichiro, Jaffe, Glenn J, Schmidt-Erfurth, Ursula, Brown, David M, Gomes, Andre V, Warburton, James, Weichselberger, Andreas, Holz, Frank G
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.01.2020
Schlagworte:	Aged Aged, 80 and over Angiogenesis Inhibitors - adverse effects Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Choroidal Neovascularization - drug therapy Choroidal Neovascularization - physiopathology Double-Blind Method Female Humans Intravitreal Injections Male Middle Aged Receptors, Vascular Endothelial Growth Factor - therapeutic use Recombinant Fusion Proteins - adverse effects Recombinant Fusion Proteins - therapeutic use Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - physiology Wet Macular Degeneration - drug therapy Wet Macular Degeneration - physiopathology
ISSN:	1549-4713, 1549-4713
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!